Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age14+
SponsorDaihong Liu
About this trial
The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for grade II acute GVHD (graft-versus-host disease )
Eligibility criteria
Qualifiers
Diagnosed with hematological diseases.
Have undergone first allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies.
New onset of grade II acute GVHD or intermediate or high risk aGVHD (based on modified GVHD Glucksberg criteria) within 100 days post-transplantation.
Disqualifiers
Recipients of second allogeneic stem cell transplant.
Acute GVHD induced by donor lymphocyte infusion, interferon.
Received first line aGVHD treatment before enrollment.
Overlap GVHD syndrome.
Trial design
Treatments tested in this trial
- Ruxolitinib
- Corticosteroids
Treatment groups
168 Participants
are divided into 2 treatment groupsSponsors and collaborators
Daihong Liu
Lead sponsor
Chinese PLA General Hospital
Sponsor institution
Source ClinicalTrials.gov